Spire Healthcare Group has delivered a strong 46.4% gain year to date, which puts fresh focus on whether the current share price lines up with the revenue the business is generating. For anyone looking at the stock today, the real issue is how much sales investors are effectively paying for after that move.
- The 46.4% rise year to date concentrates attention on whether the recent share price now fully reflects the hospital operator's current level of sales.
- Spire Healthcare Group's model, built around UK private and NHS-funded hospital services, means future revenue growth, margins and capital spending needs can all influence how much investors are prepared to pay for each pound of sales.
- Your read on Spire Healthcare Group is one view; the desks covering it have another. See what analysts think Spire Healthcare Group's shares could be worth.
The stock's next move may depend on whether today's valuation is justified by Spire Healthcare Group's sales base and how that revenue is being converted into sustainable profit and cash flow.
If you are weighing whether Spire Healthcare Group's 46.4% year to date gain still lines up with its sales, it can help to compare that question across 15 high quality undervalued stocks.
Is Spire Healthcare Group Still Cheap on Sales?
The P/S ratio works reasonably well for Spire Healthcare Group because healthcare providers often have meaningful revenue long before accounting profit looks smooth. On this measure, the shares trade on roughly 0.6x trailing sales, which is below both the Healthcare industry average of about 1.3x and a broader peer group closer to 2.1x.
The fair multiple implied by Simply Wall St's model, which blends the group's margins, growth profile, size and risk, sits higher than where the stock trades today. That gap suggests the market is currently pricing Spire Healthcare Group at a discount to what those fundamentals might justify, although the durability of its revenue, capital intensity of hospitals and exposure to NHS contract dynamics are all factors you would still want to test for yourself before leaning on the P/S signal too heavily. Explore the numbers behind Spire Healthcare Group's P/S valuation.
The Spire Healthcare Group Narrative: What Would Justify Today's Price?
Spire Healthcare Group's Simply Wall St Narratives pick up where the P/S puzzle leaves off and explain what path for growth, margins and earnings would need to occur for the stock to be worth meaningfully more or less than it is today on the market. Each Narrative treats Spire Healthcare Group's implied worth as a specific, testable story about the business that you can track over time, and they are available on the Community page for you to review.
One of the top narratives on Spire Healthcare Group: 6% undervalued
This Narrative is the analyst consensus Narrative on Simply Wall St, which compiles analysts' consensus price target and revenue and earnings forecasts, not one person's view.
"Ongoing transformation, centralisation and digital and AI programmes, including more than £30m of targeted cost savings for 2026 after £30m delivered in 2025…"
Discover why this Narrative puts Spire Healthcare Group at 6% undervalued.
One big loose end on Spire Healthcare Group
The valuation picture for Spire Healthcare Group only tells part of the story, because professional analysts have already sketched out where they think this hospital operator could be a few years from now. Explore where analysts expect Spire Healthcare Group to be in a few years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com